MedTrace Logo

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

NCT00329043 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2025-12-26

No results posted yet for this study

Summary

The goal of this clinical research study is to learn if the addition of sunitinib malate (SU011248) to hormone based castration is an effective treatment for shrinking or controlling the tumor before having the prostate removed.

Conditions

Interventions

DRUG

LHRH Agonist

Intramuscular injection either monthly for 3 months or in a single 3-month dose.

DRUG

Sunitinib Malate

25 to 37.5 mg/day once daily for 30 days (= 1 cycle), up to 3 cycles.

PROCEDURE

Radical Prostatectomy

Radical prostatectomy after completion of Sunitinib and LHRH agonist.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Amado Zurita, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-15
Primary Completion
2027-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00329043 on ClinicalTrials.gov